Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver Disease (AASLD) meeting. Here's what you need to know.
What To Know: Tharimmune, a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, presented positive clinical data from a Phase I trial of TH104, a potential treatment for chronic pruritus in chronic liver disease.
The clinical data showed that higher levels of TH104 in the blood were associated with a reduction in itching, a common symptom of chronic pruritus. The treatment also appeared safe, with no serious side effects reported.
"We look forward to initiating a Phase 2 multiple-ascending dose trial in the coming months to evaluate TH104 in chronic pruritus in primary biliary cholangitis (PBC) patients, with topline data expected in 2025. In the meantime, we continue to engage with both U.S. and EU regulatory authorities," said Randy Milby, CEO of Tharimmune.
How To Buy THAR Shares
By now you're likely curious about how to participate in the market for Tharimmune – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy 'fractional shares,' which allows you to own portions of stock without buying an entire share.
In the case of Tharimmune, which is trading at $1.93 as of publishing time, $100 would buy you 51.81 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to 'go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
THAR Price Action: At the time of publication, Tharimmune shares were down 8.29% at $1.99, according to data from Benzinga Pro.
Image: Photo by roberto-sorin for Unsplash
